Opinion
Video
Author(s):
Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these collective data have changed perspectives on frontline therapies for ALK+ non–small cell lung cancer (NSCLC).
Real-World Settings and Evolution of Frontline Therapy
Key Themes:
Notable Insights:
Dr Dietrich summarized how recent clinical data has changed the landscape of frontline therapies for ALK+ NSCLC